このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Laboratorios Farmaceuticos Rovi バランスシートの健全性
財務の健全性 基準チェック /56
Laboratorios Farmaceuticos Roviの総株主資本は€523.8M 、総負債は€81.8Mで、負債比率は15.6%となります。総資産と総負債はそれぞれ€778.7Mと€254.9Mです。 Laboratorios Farmaceuticos Roviの EBIT は€178.1Mで、利息カバレッジ比率-556.6です。現金および短期投資は€13.1Mです。
主要情報
15.6%
負債資本比率
€81.77m
負債
| インタレスト・カバレッジ・レシオ | -556.6x |
| 現金 | €13.09m |
| エクイティ | €523.78m |
| 負債合計 | €254.88m |
| 総資産 | €778.66m |
財務の健全性に関する最新情報
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Apr 17
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Dec 21Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Aug 26Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
May 26Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Feb 22These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Nov 04Recent updates
We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Jun 17Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
May 08These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Apr 17Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Feb 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Dec 21Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Nov 03Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Aug 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jul 14Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
May 26Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
May 05Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Apr 11Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Feb 22An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
Dec 10These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Nov 04Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
Sep 15Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Aug 28Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Jun 15I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease
Feb 13Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Jan 02A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Dec 12Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Nov 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Sep 24Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Jun 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Apr 06Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%
Mar 15If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late
Feb 16
Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?
Jan 26These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Jan 04Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years
Dec 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?
Nov 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jul 06財務状況分析
短期負債: ROVIの 短期資産 ( €485.4M ) が 短期負債 ( €191.2M ) を超えています。
長期負債: ROVIの短期資産 ( €485.4M ) が 長期負債 ( €63.6M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: ROVIの 純負債対資本比率 ( 13.1% ) は 満足できる 水準であると考えられます。
負債の削減: ROVIの負債対資本比率は、過去 5 年間で10.1%から15.6%に増加しました。
債務返済能力: ROVIの負債は 営業キャッシュフロー によって 十分にカバー されています ( 127.5% )。
インタレストカバレッジ: ROVI支払う利息よりも稼ぐ利息の方が多いので、利息支払い の補償は問題になりません。